Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Once every 3 weeks or once every 4 weeks intravenously injection”In the company’s words, NCT07530666 on ClinicalTrials.gov
- Main trialPhase 1/2
- “A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia”In the company’s words, NCT07530666 on ClinicalTrials.gov
Other drugs for Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- 30 Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 16 Jun 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 30 Oct 2027 | Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia | |
| Phase 1/2Recruiting | 16 Jun 2028 | Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026